Which has better earnings & valuation, NPCE or NVCR?

NeuroPace has higher earnings, but lower revenue than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 4.35 -$21.47M -$0.57 N/A NovoCure $655.35M 2.59 -$136.23M -$1.30 N/A

Is NPCE or NVCR more profitable?

NeuroPace has a net margin of -19.34% compared to NovoCure's net margin of -21.25%. NovoCure's return on equity of -44.00% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -19.34% -105.64% -16.51% NovoCure -21.25% -44.00% -15.85%

Which has higher earnings & valuation, ATEC or NPCE?

NeuroPace has lower revenue, but higher earnings than Alphatec. NeuroPace is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alphatec $764.16M 2.16 -$143.36M -$0.71 N/A NeuroPace $99.99M 4.35 -$21.47M -$0.57 N/A

Is ATEC or NPCE more profitable?

Alphatec has a net margin of -13.49% compared to NeuroPace's net margin of -19.34%. NeuroPace's return on equity of -105.64% beat Alphatec's return on equity. Company Net Margins Return on Equity Return on Assets Alphatec -13.49% -6,752.24% -13.88% NeuroPace -19.34% -105.64% -16.51%

Which has preferable earnings & valuation, OMCL or NPCE?

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.25B 1.31 $2.05M $0.84 42.64 NeuroPace $99.99M 4.35 -$21.47M -$0.57 N/A

Is OMCL or NPCE more profitable?

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 3.13% 5.66% 3.57% NeuroPace -19.34% -105.64% -16.51%

Which has better earnings and valuation, NPCE or CNMD?

CONMED has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 4.35 -$21.47M -$0.57 N/A CONMED $1.37B 0.97 $47.06M $1.85 24.02

Is NPCE or CNMD more profitable?

CONMED has a net margin of 4.12% compared to NeuroPace's net margin of -19.34%. CONMED's return on equity of 14.31% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -19.34% -105.64% -16.51% CONMED 4.12% 14.31% 6.33%

NeuroPace (NPCE) Competitors

$12.67 +0.28 (+2.26%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$12.66 -0.01 (-0.08%)

As of 10/9/2026 07:30 PM Eastern

Compare

NPCE vs. NVCR, ATEC, KMTS, OMCL, and CNMD

Should you buy NeuroPace stock or one of its competitors? NeuroPace's main competitors and comparable companies include NovoCure (NVCR), Alphatec (ATEC), Kestra Medical Technologies (KMTS), Omnicell (OMCL), and CONMED (CNMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroPace compare to NovoCure?

NeuroPace (NASDAQ:NPCE) and NovoCure (NASDAQ:NVCR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

NeuroPace has a net margin of -19.34% compared to NovoCure's net margin of -21.25%. NovoCure's return on equity of -44.00% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
NovoCure	-21.25%	-44.00%	-15.85%

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 19.2% of NeuroPace shares are held by insiders. Comparatively, 6.6% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeuroPace has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

NeuroPace has higher earnings, but lower revenue than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.35	-$21.47M	-$0.57	N/A
NovoCure	$655.35M	2.59	-$136.23M	-$1.30	N/A

In the previous week, NovoCure had 2 more articles in the media than NeuroPace. MarketBeat recorded 3 mentions for NovoCure and 1 mentions for NeuroPace. NovoCure's average media sentiment score of 0.86 beat NeuroPace's score of 0.00 indicating that NovoCure is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroPace	Neutral
NovoCure	Positive

NeuroPace currently has a consensus price target of $19.33, suggesting a potential upside of 52.59%. NovoCure has a consensus price target of $21.20, suggesting a potential upside of 45.40%. Given NeuroPace's stronger consensus rating and higher probable upside, equities research analysts plainly believe NeuroPace is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

NeuroPace beats NovoCure on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Alphatec?

Alphatec (NASDAQ:ATEC) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Alphatec has a net margin of -13.49% compared to NeuroPace's net margin of -19.34%. NeuroPace's return on equity of -105.64% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-13.49%	-6,752.24%	-13.88%
NeuroPace	-19.34%	-105.64%	-16.51%

66.4% of Alphatec shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 13.5% of Alphatec shares are owned by company insiders. Comparatively, 19.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alphatec presently has a consensus target price of $17.40, indicating a potential upside of 63.07%. NeuroPace has a consensus target price of $19.33, indicating a potential upside of 52.59%. Given Alphatec's higher probable upside, equities analysts clearly believe Alphatec is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Alphatec had 2 more articles in the media than NeuroPace. MarketBeat recorded 3 mentions for Alphatec and 1 mentions for NeuroPace. Alphatec's average media sentiment score of 0.00 equaled NeuroPace'saverage media sentiment score.

Company	Overall Sentiment
Alphatec	Neutral
NeuroPace	Neutral

NeuroPace has lower revenue, but higher earnings than Alphatec. NeuroPace is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$764.16M	2.16	-$143.36M	-$0.71	N/A
NeuroPace	$99.99M	4.35	-$21.47M	-$0.57	N/A

Alphatec has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Summary

NeuroPace beats Alphatec on 8 of the 15 factors compared between the two stocks.

How does NeuroPace compare to Kestra Medical Technologies?

NeuroPace (NASDAQ:NPCE) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

NeuroPace has higher earnings, but lower revenue than Kestra Medical Technologies. NeuroPace is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.35	-$21.47M	-$0.57	N/A
Kestra Medical Technologies	$106.73M	15.06	-$131.61M	-$2.67	N/A

NeuroPace has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

NeuroPace has a net margin of -19.34% compared to Kestra Medical Technologies' net margin of -140.43%. Kestra Medical Technologies' return on equity of -63.83% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%

NeuroPace presently has a consensus price target of $19.33, indicating a potential upside of 52.59%. Kestra Medical Technologies has a consensus price target of $28.38, indicating a potential upside of 5.17%. Given NeuroPace's stronger consensus rating and higher possible upside, equities analysts plainly believe NeuroPace is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Kestra Medical Technologies had 1 more articles in the media than NeuroPace. MarketBeat recorded 2 mentions for Kestra Medical Technologies and 1 mentions for NeuroPace. Kestra Medical Technologies' average media sentiment score of 0.54 beat NeuroPace's score of 0.00 indicating that Kestra Medical Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroPace	Neutral
Kestra Medical Technologies	Positive

78.8% of NeuroPace shares are owned by institutional investors. 19.2% of NeuroPace shares are owned by insiders. Comparatively, 5.3% of Kestra Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

NeuroPace beats Kestra Medical Technologies on 11 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Omnicell?

Omnicell (NASDAQ:OMCL) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Omnicell had 8 more articles in the media than NeuroPace. MarketBeat recorded 9 mentions for Omnicell and 1 mentions for NeuroPace. Omnicell's average media sentiment score of 0.15 beat NeuroPace's score of 0.00 indicating that Omnicell is being referred to more favorably in the media.

Company	Overall Sentiment
Omnicell	Neutral
NeuroPace	Neutral

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
NeuroPace	-19.34%	-105.64%	-16.51%

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.25B	1.31	$2.05M	$0.84	42.64
NeuroPace	$99.99M	4.35	-$21.47M	-$0.57	N/A

Omnicell has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market.

Omnicell presently has a consensus price target of $57.86, indicating a potential upside of 61.52%. NeuroPace has a consensus price target of $19.33, indicating a potential upside of 52.59%. Given Omnicell's higher probable upside, equities research analysts plainly believe Omnicell is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 2.9% of Omnicell shares are owned by insiders. Comparatively, 19.2% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Omnicell beats NeuroPace on 11 of the 16 factors compared between the two stocks.

How does NeuroPace compare to CONMED?

NeuroPace (NASDAQ:NPCE) and CONMED (NYSE:CNMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

CONMED has a net margin of 4.12% compared to NeuroPace's net margin of -19.34%. CONMED's return on equity of 14.31% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
CONMED	4.12%	14.31%	6.33%

NeuroPace has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, CONMED has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

CONMED has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.35	-$21.47M	-$0.57	N/A
CONMED	$1.37B	0.97	$47.06M	$1.85	24.02

NeuroPace presently has a consensus target price of $19.33, suggesting a potential upside of 52.59%. CONMED has a consensus target price of $41.40, suggesting a potential downside of 6.82%. Given NeuroPace's stronger consensus rating and higher probable upside, equities analysts clearly believe NeuroPace is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
CONMED	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

78.8% of NeuroPace shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Comparatively, 0.3% of CONMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, CONMED had 3 more articles in the media than NeuroPace. MarketBeat recorded 4 mentions for CONMED and 1 mentions for NeuroPace. CONMED's average media sentiment score of 0.51 beat NeuroPace's score of 0.00 indicating that CONMED is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroPace	Neutral
CONMED	Positive

Summary

CONMED beats NeuroPace on 9 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$425.28M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-22.23	25.57	274.15	26.16
Price / Sales	4.35	83.27	590.50	94.68
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	22.23	5.93	11.21	6.34
Net Income	-$21.47M	$146.18M	$3.50B	$381.90M
7 Day Performance	-0.24%	-0.38%	-0.90%	-1.41%
1 Month Performance	-8.65%	-2.02%	-4.44%	-3.48%
1 Year Performance	23.25%	5.08%	6.96%	1.16%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	3.1341 of 5 stars	$12.67 +2.3%	$19.33 +52.6%	+17.4%	$425.28M	$99.99M	N/A	220
NVCR NovoCure	3.0251 of 5 stars	$14.92 -1.8%	$21.20 +42.1%	+1.7%	$1.74B	$699.19M	N/A	1,605	News Coverage Analyst Downgrade
ATEC Alphatec	3.4903 of 5 stars	$10.58 -1.4%	$17.40 +64.5%	-22.5%	$1.63B	$764.16M	N/A	913
KMTS Kestra Medical Technologies	1.5974 of 5 stars	$27.10 -4.4%	$28.38 +4.7%	+14.9%	$1.61B	$95.13M	N/A	443
OMCL Omnicell	4.0137 of 5 stars	$35.09 +1.3%	$57.86 +64.9%	+15.1%	$1.60B	$1.18B	41.77	3,580

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors